Rep. Robert Bresnahan, Jr. Purchases Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in West Pharmaceutical Services stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

West Pharmaceutical Services Trading Down 1.8 %

Shares of West Pharmaceutical Services stock traded down $3.98 during mid-day trading on Friday, hitting $222.08. 496,755 shares of the stock were exchanged, compared to its average volume of 664,265. The company has a 50-day simple moving average of $263.98 and a 200 day simple moving average of $297.88. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $16.06 billion, a price-to-earnings ratio of 33.20, a price-to-earnings-growth ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services, Inc. has a twelve month low of $197.01 and a twelve month high of $396.75.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.07. The company had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. Research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio is presently 12.56%.

Institutional Trading of West Pharmaceutical Services

Several large investors have recently modified their holdings of WST. Bank of New York Mellon Corp grew its stake in West Pharmaceutical Services by 6.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,449,811 shares of the medical instruments supplier’s stock valued at $1,130,020,000 after purchasing an additional 203,198 shares in the last quarter. State Street Corp increased its stake in shares of West Pharmaceutical Services by 0.3% in the third quarter. State Street Corp now owns 3,214,448 shares of the medical instruments supplier’s stock worth $964,850,000 after buying an additional 10,060 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in West Pharmaceutical Services by 1.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,110,903 shares of the medical instruments supplier’s stock valued at $1,019,007,000 after acquiring an additional 44,376 shares in the last quarter. Brown Advisory Inc. boosted its stake in West Pharmaceutical Services by 11.7% during the 4th quarter. Brown Advisory Inc. now owns 2,552,036 shares of the medical instruments supplier’s stock valued at $835,945,000 after acquiring an additional 266,488 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in West Pharmaceutical Services by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,778,940 shares of the medical instruments supplier’s stock worth $581,209,000 after acquiring an additional 38,757 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on WST shares. Citigroup started coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, February 27th. Evercore ISI began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 price target on the stock. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a research note on Friday, February 14th. Finally, KeyCorp lowered their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $332.50.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.